Compare IDEXX Laboratories, Inc. (IDXX) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs United Airlines Holdings Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while United Airlines Holdings Inc trades at $107.46 (market cap $34.87B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and United Airlines Holdings Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and United Airlines Holdings Inc for 46 Days on average.
| IDXX | UAL | |
|---|---|---|
Market Cap | $40.43B | $34.87B |
Volume | 692,164 | 6,329,678 |
Sector | Health | Industrials |
52-Week High | $766.68 | $136.11 |
52-Week Low | $504.70 | $85.21 |
Typical Hold Time | 46 Days | 46 Days |
Enterprise Value | $41.32B | $51.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
United Airlines (UAL) trades at $107.44, down 2.48% on the day, reflecting near-term pressure amid a bearish technical signal. Fundamentally, the company shows strength with a low P/E of 10.06, robust ROE of 23.25%, and consistent earnings beats in recent quarters. Recent news highlights aggressive customer acquisition efforts targeting Delta and American Airlines' premium flyers, leveraging Starlink WiFi partnerships to enhance its competitive edge.
The outlook is mixed: strong analyst consensus (66% buy ratings) and a $158.10 price target suggest upside, but rising fuel costs and bearish technicals pose near-term risks. Earnings sustainability and market share gains from strategic moves are key catalysts, while volatility in travel demand remains a headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
